VivoSeq
Gastroenterology

Celiac Disease

48

Pipeline Programs↗

11

Active Trials↗

22

Companies Involved↗

Celiac Disease is a moderately active landscape with 48 programs across 22 companies. The most active players are Roche, Johnson & Johnson, Barinthus Biotherapeutics. 8 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

19/100

Mech. Concentration

10/100

Completion Rate

88/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1B

Barinthus Biotherapeutics

1 program

Phase 1Protagonist Therapeutics logo

Protagonist Therapeutics

1 program

Phase 1Amgen logo

Amgen

3 programs

Phase 29

9 Meters Biopharma, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

38 of 44 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody37%Protein / enzyme25%Vaccine12%

Small molecule leads; the ring shows all 44 classified programs, each share of the total. Modality classified for 94% of 53 pipeline programs.

Analysis

Trial Status

60

clinical trials

Completed38 · 63%
Recruiting7 · 12%
Unknown status6 · 10%
Terminated4 · 7%
Active, not recruiting3 · 5%
Not yet recruiting1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

60 trials

Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission
Recruiting·MMassachusetts General Hospital·Phase 2·NCT05636293·40 enrolled
Tryptophan for Impaired AhR Signaling in Celiac Disease
Recruiting·MMcMaster University·N/A·NCT05576038·50 enrolled
A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
Recruiting·—·Phase 1·NCT07063823·18 enrolled
Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease
Recruiting·FForte Biosciences, Inc.·Phase 2·NCT06982963·100 enrolled
Study of DONQ52 in Active Celiac Disease
Recruiting·Roche logoRoche·Phase 2·NCT07239336·92 enrolled
VTP-1000 in Adults With Celiac Disease
Recruiting·BBarinthus Biotherapeutics·Phase 1·NCT06310291·45 enrolled
A First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
Recruiting·—·Phase 1·NCT07377565·20 enrolled
Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease
Active, not recruiting·—·Phase 2·NCT07298343·356 enrolled
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
Active, not recruiting·Sanofi logoSanofi·Phase 2·NCT06557772·229 enrolled
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure
Active, not recruiting·Teva logoTeva·Phase 2·NCT06807463·50 enrolled
Iron Deficiency in Pediatric Celiac Disease: Diet vs. Iron Supplementation Trial
Not yet recruiting·KKaplan Medical Center·N/A·NCT06921343·150 enrolled
PTG-100 for Patients With Celiac Disease
Completed·—·Phase 1·NCT04524221·12 enrolled
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet
Completed·Takeda logoTakeda·Phase 2·NCT05353985·153 enrolled
Safety and Efficacy of ALV003 for the Treatment of Celiac Disease
Completed·AAlvine Pharmaceuticals Inc.·Phase 2·NCT00959114·74 enrolled
Antibody Treatment for Advanced Celiac Disease
Completed·National Cancer Institute (NCI)·Phase 1·NCT01893775·5 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)